Hyperfine

HYPR

Market cap $102M

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR) (“Hyperfine” or the “Company”) today announced it has priced its previously announced underwritten public offering of 14,000,000 shares of the Company's Class A common stock at a public offering price of $1.25 per share. All of the shares in the offering are being sold by Hyperfine. In addition, Hyperfine has granted the underwriter a 30-day option to purchase up to 2,100,000 shares of Class A common stock, which equals 15% of the.

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR) (“Hyperfine” or the “Company”) today announced that it has commenced an underwritten public offering of its Class A common stock or, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase Class A common stock. All securities to be sold in the offering will be sold by Hyperfine. In addition, Hyperfine intends to grant the underwriters a 30-day option to purchase up to 15% of the total number of securi.

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced preliminary, unaudited financial results for the third quarter ended September 30, 2025. “In the third quarter, we saw strong market excitement and demand for our next generation Swoop® system and Optive AI™ software, evidenced by our ability to qui.

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine Swoop® system, via partner UpCare, earns national referencing from UniHA, France's top hospital purchasing cooperative.

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine launches a subscription-based platform designed to empower researchers and developers advancing access and innovation in portable MRI.

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine announces it has received CE Marking and UK Conformity Assessment (UKCA) approval for its Optive AI™ software.

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced their schedule for upcoming investor conferences. Hyperfine will discuss with investors recently announced milestones and growth catalysts, including its two major new technology clearances, commercial launch and market feedback.

Hyperfine (HYPR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Hyperfine, Inc. (NASDAQ:HYPR ) Q2 2025 Earnings Conference Call August 13, 2025 4:30 PM ET Company Participants Brett Hale - Chief Administrative Officer, CFO, Chief Compliance Officer, Treasurer & Corporate Secretary Maria Sainz - CEO, President & Director Conference Call Participants Brandon Carney - B. Riley Securities, Inc., Research Division Frank James Takkinen - Lake Street Capital Markets, LLC, Research Division Gursimran Kaur - Wells Fargo Securities, LLC, Research Division Webb Campbell - Unidentified Company Operator Good afternoon, and welcome to Hyperfine's Second Quarter 2025 Earnings Conference Call.

Hyperfine, Inc. (HYPR) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.14 per share a year ago.